Skip to Main
Investment Banking

Strong Momentum Continues in 2021

  • Oppenheimer & Co. Inc.
  • March 1, 2021

An Important Message to Our Clients From Your Healthcare Investment Banking Team

Oppenheimer Healthcare had a strong start to 2021, raising over $3.4B in financings year-to-date as well as closing a sell side M&A transaction.

Healthcare Transactions
Healthcare Transactions

As part of our commitment to clients, we are available at any time. Please feel free to reach out to your investment banking representative.

Michael Margolis
Name:

Michael Margolis, R.Ph.

Title:

Managing Director, Co-Head of Healthcare Investment Banking

Contact

212-667-7622 MichaelA.Margolis@opco.com

85 Broad Street
23rd Floor
New York, New York 10004

Hide Bio
James O’Neill
Name:

James O’Neill

Title:

Managing Director, Head of Healthcare ECM

Address

85 Broad Street
23rd Floor
New York, NY 10004Click to open address in a new window on Google Maps

Contact

(212) 667-6438 James.Oneill@opco.com
Hide Bio

DISCLOSURE

This document is for discussion purposes only and does not constitute advice of any kind, including tax, accounting, legal or regulatory advice, and Oppenheimer & Co. Inc. Is not and does not hold itself out to be an advisor as to tax, accounting, legal or regulatory matters.

The information contained herein was obtained from public sources and was relied upon by Oppenheimer & Co. Inc. Without assuming responsibility for independent verification as to the accuracy or completeness of such information. No representation or warranty, express or implied, is made as to the accuracy or completeness of such information and nothing contained herein is, or shall be relied upon as, a representation or warranty, whether as to the past or the future. Oppenheimer & Co. Inc. Assumes no obligation to update or otherwise revise these materials.

Oppenheimer & Co. Inc.’s research department is required to be independent from its investment banking department, and its research analysts may hold and make statements or investment recommendations that differ from the views of its investment bankers. Further, pursuant to applicable law, Oppenheimer & Co. Inc. Is (among other things) precluded from offering favorable research, a specific rating or a specific price target, or threaten to change research, a rating or a price target, as consideration or inducement for the receipt of business or compensation.